Search filters
Filters
Clear All

Phase

  • 24
  • 4
  • 20
  • 31
  • 1
  • 9
  • 92
  • 62
  • 1
  • 1
  • 90

Found 92 Vision Loss trials

A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Randomized Double-Blind Placebo-Controlled Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab Ramucirumab and Paclitaxel in Subjects With Previously Treated Locally-Advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)

A Randomized Double-Blind Placebo-Controlled Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab Ramucirumab and Paclitaxel in Subjects With Previously Treated Locally-Advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)

19 years - 99 years
All genders
This study is being done to see if tucatinib with trastuzumab, ramucirumab and paclitaxel works better than ramucirumab and paclitaxel to treat HER2-positive (HER2+) cancer of the gut (stomach or gastroesophageal cancer). This study will also look at what side effects happen when participants take this combination of drugs
Learn More
A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain.

A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain.

40 years - 90 years
All genders
Interventional
The purpose of this study is to evaluate the safety and efficacy of CNTX-6970. The target population is adults between 40 - 90 years old who have moderate to severe knee pain related to OA. The study drug is being compared to Celebrex, an FDA approved drug used to treat …
Learn More

A Multicenter Randomized Double-Blind Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

99 years or below
All genders
Phase 3
The study will enroll subjects who have completed Study M16-067 or Study M16-065 and have achieved clinical response, defined as decrease from Baseline of induction study of Adapted Mayo score greater than or equal to 2 points and greater than or equal to 30%, PLUS a decrease in rectal bleeding …
Learn More

UPCC 08320 Phase 3 Randomized Double-blind Multicenter Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with an Immune Checkpoint Inhibitor

99 years or below
All genders
TBD
Learn More

UPCC 03722 A prospective randomized double-blind placebo-controlled multi-center phase IIb study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)

99 years or below
All genders
The purpose of this study is to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
Learn More

A Phase 2a/b Randomized Double-blind Placebo-controlled Parallel Group Multicenter Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels in Women 18 to 49 Years of Age with Moderate to Severe Endometriosis-related Pain

99 years or below
All genders
A study to investigate efficacy and safety of OG-6219 BID in 3 dose levels compared with Placebo in participants aged 18 to 49 with moderate to severe endometriosis-related pain
Learn More
UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

18 years - 99 years
All genders
Phase 3
The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.
Learn More

A Global Phase 2 Randomized Double-Blind Placebo-Controlled Dose-Ranging Study of BMS-986177 an Oral Factor XIa Inhibitor for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)

99 years or below
All genders
Phase 2
See full protocol for details.
Learn More

UPCC 15820: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

99 years or below
All genders
The purpose of this study is to see if niraparib added to a standard treatment (abiraterone acetate and prednisone) will work better than abiraterone acetate and prednisone alone in treating men with metastatic prostate cancer with specific genetic changes. Eligible subjects will be men with metastatic prostate cancer.
Learn More

UPCC 12122 SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibit

99 years or below
All genders
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib or abemaciclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation
Learn More
51 - 60 of 92